Study S002614

Strict Weight Management and Glycemic Control Based on Glucagon-like Peptide-1 (GLP-1) Receptor Agonist Treatment VS. Conventional Antidiabetic Drugs for Ablation Outcomes in Overweight or Obese Patients with Type 2 Diabetes and Atrial Fibrillation

ClinicalTrials.gov record

Registration

Registration: NCT06660134
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Masking: NONE
Status: COMPLETED
Enrollment: 174
Start: 2021-08-01
Primary completion: 2023-12-31
Lead sponsor: Shanghai Chest Hospital
Conditions: Type 2 Diabetes Mellitus (T2DM); Atrial Fibrillation (AF)
Interventions: DRUG:Glucagon-like peptide-1 receptor agonists (GLP 1 RA)
Results posted: FALSE
Individual participant data sharing: UNDECIDED

Registered primary outcomes

Atrial fibrillation (AF), atrial flutter (AFL), or atrial tachycardia events lasting ≥30 seconds occurring from the end of a 3-month blanking period post-procedure up to 12 months of follow-up. [at least 12 months of follow-up, beyond the initial 3-month blanking period]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.